Benefits
Distinct Absorption Pathway (HCP1)
Heme iron uses the HCP1 (heme carrier protein 1) transporter — DIFFERENT from non-heme iron's DMT1 pathway. Means heme iron absorption is NOT affected by phytates, polyphenols, calcium, or PPI use. Reliable absorption with meals.
Up to 21% Absorption Rate
Heme iron polypeptide absorbed at ~21% efficiency vs ~0.1-2% for ferrous gluconate when taken WITH MEALS. Even compared to fasting ferrous sulfate (~10-15%), heme iron is substantially better-absorbed when timing is convenient (with meals).
Minimal GI Side Effects
Heme iron polypeptide causes substantially fewer GI symptoms than ferrous salts — less constipation, less nausea, less metallic taste. Bound iron means no free Fe²⁺ irritating mucosa.
No Drug Interaction with Calcium/PPIs
Unlike ferrous salts, heme iron absorption is NOT meaningfully reduced by calcium, PPIs, antacids, coffee, or tea. Patients on chronic acid suppression (very common) maintain iron absorption.
IBD/Crohn's/Bariatric Surgery Patients
Heme iron may be preferred form for IBD patients (gentler), bariatric surgery patients (altered iron absorption pathways), and chronic PPI users — populations where ferrous salt absorption is problematic.
Mechanism of action
HCP1 (Heme Carrier Protein 1) Transport
Heme iron is absorbed intact via HCP1 transporter on duodenal enterocyte apical membrane. Inside the cell, heme oxygenase releases iron from the porphyrin ring; the iron is then exported via ferroportin like other iron sources.
Bypass of Iron Absorption Inhibitors
Phytates, polyphenols, calcium, oxalates inhibit DMT1 absorption of non-heme iron. Heme is absorbed intact through HCP1, bypassing all these inhibitors.
Animal Source Polypeptide Matrix
HIP is derived from animal (typically porcine or bovine) hemoglobin — partially digested to produce a heme-peptide complex. Mimics dietary heme iron from red meat (the most bioavailable dietary iron form).
Reduced Mucosal Irritation
No free Fe²⁺ in GI lumen means no oxidative damage to mucosal cells — basis for substantially better tolerability.
Clinical trials
RCT comparing heme iron polypeptide vs ferrous fumarate for absorption when taken with meals.
Adults with iron deficiency.
When taken with meals, HIP iron absorption was significantly higher than ferrous fumarate. Side effects substantially fewer with HIP. Established HIP's value for meal-time iron supplementation.
Open-label studies of HIP in pregnant women with IDA who could not tolerate ferrous salts.
Pregnant women with IDA + sulfate intolerance.
HIP raised hemoglobin in pregnancy IDA with minimal side effects. Open-label limitation; not direct comparison to bisglycinate or sulfate at equivalent elemental doses.